Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.

Abstract

5-[4-(2-Carboxyethylcarbamoyl)phenylazo]salicylic acid disodium salt dihydrate (CAS 80573-04-2, BX661A) is developed as a therapeutic agent for ulcerative colitis. To clarify the mechanisms of action of BX661A, the effects of BX661A and its metabolites 5-aminosalicylic acid (5-ASA) and 4-aminobenzoyl-beta-aline (4-ABA) on polymorphonuclear (PMN) leukocyte chemotaxis and production of reactive oxygen species (ROS) from PMN cells were investigated and compared with the effects of 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-benzoic acid (CAS 599-79-1, SASP) and its metabolite 4-amino-N-2-pyridinyl-benzenesulfonamide (CAS 144-83-2, SP). 1. BX661A, SASP and SP concentration-dependently inhibited guinea pig PMN cell chemotaxis induced by zymosan-activated serum (IC50 = 1.39, 2.17 mmol/l, respectively) and by N-formyl-methionyl-leucyl-phenylalanine (FMLP) with IC50 values of 0.55, 0.06 and 0.66 mmol/l, respectively. 5-ASA and 4-ABA weakly affected the PMN cell chemotaxis induced by zymosan-activated serum (both IC50 values > or = 10 mmol/l) and by FMLP (IC50 > or = 10 and 8.05 mmol/l, respectively). 2. BX661A, SASP and SP concentration-dependently inhibited human PMN cell chemotaxis induced by FMLP with IC50 values of 0.68, 0.05 and 2.68 mmol/l, respectively, but both IC50 values of 5-ASA and 4-ABA were > 10 mmol/l. 3. BX661A, SASP, 5-ASA, 4-ABA and SP inhibited ROS production from rat PMN cells stimulated by FMLP in a concentration-dependent manner (IC50 = 58.4, 27.5, 0.61, 1242 and 13.9 mmol/l, respectively). 4. BX661A, SASP, 5-ASA, 4-ABA and SP inhibited ROS production from human PMN cells stimulated by FMLP in a concentration-dependent manner (IC50 = 67.4, 46.1, 0.69, 748 and 8.31 mumol/l, respectively). These results suggest that BX661A itself has inhibitory effects against PMN cell chemotaxis and ROS production from PMNs and that 5-ASA, which is the active moiety of BX661A, has a potent inhibitory effect against ROS production from PMNs. Therefore, these effects may be partially involved in the therapeutic effects of BX661A on ulcerative colitis.

• Authors: I Kimura, M Kawasaki, A Matsuda, M Kataoka, Y Kokurba
• Journal: Arzneimittel-Forschung (Arzneimittelforschung) Vol. 48 Issue 12 Pg. 1163-7 (Dec 1998) ISSN: 0004-4172 [Print] Germany
• PMID: 9893931 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Aminosalicylic Acids
• Anti-Ulcer Agents
• Phenylhydrazines
• Reactive Oxygen Species
• Sulfasalazine
• Mesalamine
• balsalazide
• Sulfapyridine

Topics

• Aminosalicylic Acids (therapeutic use)
• Animals
• Anti-Ulcer Agents (therapeutic use)
• Chemotaxis, Leukocyte (drug effects)
• Colitis, Ulcerative (drug therapy)
• Guinea Pigs
• Humans
• In Vitro Techniques
• Male
• Mesalamine
• Neutrophils (drug effects, metabolism)
• Phenylhydrazines
• Rats
• Rats, Sprague-Dawley
• Reactive Oxygen Species (metabolism)
• Sulfapyridine (pharmacology)
• Sulfasalazine (pharmacology)